Monkeypox vaccine-maker’s revenue doubles since 2021

After scrambling to fill global orders for its monkeypox vaccine, Bavarian Nordic raked in $1 billion in its third quarter — more than twice its revenue in the same period last year, which was $449 million. 

Advertisement

The Denmark-based pharmaceutical company said the “all-time high revenues” were largely because of its product sales. So far this year, more than 1 million people have received its Jynneos vaccine — the only approved monkeypox vaccine in the world — and Bavarian Nordic is working on “significant orders” for 2023. 

In the first nine months of 2022, the drugmaker has made $1.86 billion in revenue, which is up 37 percent from last year’s figures.

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.